Rocket Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Rocket Pharmaceuticals, Inc. (RCKT) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $127.13 million as of 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2018-03-07
- 2017-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $127.13M.
- 2016-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $105.34M.
- 2015-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $88.44M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic |
|---|---|
| 2017-12-31 | $127.13M 10-K · filed 2018-03-07 |
| 2016-12-31 | $105.34M 10-K · filed 2017-03-16 |
| 2015-12-31 | $88.44M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |